Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial-Reference-Cited by-同舟云学术

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Published:2021-09 Issue:9 Volume:9 Page:1010-1020
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Butler Christopher C,Yu Ly-Mee,Dorward Jienchi,Gbinigie Oghenekome,Hayward Gail,Saville Benjamin R,Van Hecke Oliver,Berry Nicholas,Detry Michelle A,Saunders Christina,Fitzgerald Mark,Harris Victoria,Djukanovic Ratko,Gadola Stephan,Kirkpatrick John,de Lusignan Simon,Ogburn Emma,Evans Philip H,Thomas Nicholas P B,Patel Mahendra G,Hobbs F D Richard

Funder

UK Research and Innovation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Therapy for early COVID-19: a critical need;Kim;JAMA,2020

2. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease;Yates;Ther Adv Respir Dis,2020

3. Doxycycline as a potential partner of COVID-19 therapies;Malek;IDCases,2020

4. In vitro antiviral activity of doxycycline against SARS-CoV-2;Gendrot;Molecules,2020

5. Doxycycline modulates nitric oxide production in murine lung epithelial cells;Hoyt;J Immunol,2006

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes;Journal of Infection;2024-10

2. Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial;The Lancet Infectious Diseases;2024-09

3. Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action;Heliyon;2024-08

4. Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial;The Lancet Respiratory Medicine;2024-08

5. Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial;Journal of Clinical Medicine;2024-07-24